Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genflow Biosciences Plc ( (GB:GENF) ).
Genflow Biosciences Plc has announced progress in its pioneering Dog Aging (GF-1004) study, a clinical trial testing the safety and efficacy of its SIRT6-centenarian gene therapy on elderly dogs. The trial, which involves 28 beagles, has reported no adverse effects, marking a significant step towards securing a licensing agreement with an animal health company. The study aims to extend the lifespan and improve the quality of life in dogs, with potential applications for human health. Success in this trial could enhance Genflow’s market positioning in the high-value companion animal segment and open new avenues in longevity therapeutics.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with R&D facilities in Belgium, focusing on pioneering gene therapies to slow down the aging process. The company aims to promote longer and healthier lives, addressing the financial, emotional, and social impacts of an aging global population. Genflow’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, showing promising preclinical results.
Average Trading Volume: 5,365,597
Technical Sentiment Signal: Sell
For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.